Methadone in the treatment of cancer pain: The experience of Hospital Los Montalvos, Salamanca;Metadona en el tratamiento del dolor por cáncer: Experiencia del Hospital Los Montalvos, Salamanca

Medicina Paliativa

Volumn 11, Issue 3, 2004, Pages 157-163

  Centeno, Carlos ^a   Sanchez R ^a   Vara, F ^a  

^a Hospital Los Montalvos   (Spain)

Author keywords

Methadone; Neuropathic pain; Opioid neurotoxicity; Opioid rotation; Palliative Care

Indexed keywords

FENTANYL; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ANALGESIA; ANUS CANCER; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER PAIN; CANCER PALLIATIVE THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MALE; MEDICAL RECORD; METHADONE TREATMENT; NEUROPATHIC PAIN; NEUROTOXICITY; PANCREAS CANCER; RECTUM CANCER; RETROSPECTIVE STUDY; SPAIN; STOMACH CANCER; TERMINALLY ILL PATIENT; UTERINE CERVIX CANCER; VULVA CANCER;

EID: 7944236617     PISSN: 1134248X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain 1993; 52: 137-47.
2. Hewitt DJ. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain 2000; 16 (Supl. 2): S73-S79.
3. Elliott K, Minami N, Kolesnikov Y, et al. The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to the kappa opioids. Pain 1994; 56: 69-75.
4. Vara FJ, García EJ, Garzón N, Centeno C. El uso de metadona en el tratamiento del dolor del enfermo terminal. Libro de Abstract del V Congreso de la Sociedad Española de Dolor, p. 118-9.
5. Bruera E, Schoeller T, Wenk R, MacEachern T, Marcelino S, Hanson J, et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. Journal of Pain & Symptom Management 1995; 10 (5): 348-55.
6. Davis MP, Wals D. Methadone for relief of cancer pain: a review of pharmacodymanics, drug interactions and protocols of administration. Support Care Cancer 2001; 9: 73-83.
7. Inturrisi CE. Disposition of narcotics and narcotic antagonists. Ann NY Acad Sci 1976; 281: 273-88.
8. Nilsson MI, Meresaar U, Anggard E. Clinical pharmacokinetics of methadone. ACTA Anaesth Scand 1982 (Supl. 74): 66-9.
9. Sawe J, Hansen J, Ginman C, Hartvig P, Jakobsson PA, Nilsson MI, et al. Patient-controlled dose regimen of methadone for chronic cancer pain. Br Med J 1981; 282: 771-3.
10. Bruera E, Palmer JL, Bosnjak S, Rico MA, Moyano J, Sweeney C, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004; 22: 185-92.
11. Gagnon B, Bruera E. Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage 1999; 18: 120-5.
12. Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001; 19: 2898-904.
13. Beaver WT, Wallenstein SL, Houde RW, Rogers A. A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly, and of orally and parenterally administered methadone. Clin Pharmacol Ther 1967; 8: 415-26.
14. Caler BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain 1992; 49: 87-91.
15. MacDonald N, Der L, Allan S, et al. Opioid hyperexcitability: the application of alternate therapy. Pain 1993; 53: 353-5.
16. Sweeney N, Denson D. Clinical efficacy of methadone in patients refractory to other non-opioid receptor agonist analgesics. Cancer 1993; 72: 2266-72.
17. Mercadante S, Casuccio A, Agnello A, Serreta R, Calderone L, Barresi L. Morphine versus methadone in the pain treatment of advanced-cancer patients follow up at home. Journal of Clinical Oncology 1998; 16 (11): 3656-61.
18. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain. What is the equianalgesic dose ratio? J Clin Oncol 1998; 16: 3216-21.
19. Bruera E, Neumann C. Role of methadone in the management of pain in cancer patients. Oncology (huntingt) 1999; 13 (9): 1275-82.
20. Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients with cancer pain. A retrospective comparisin of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996; 78: 852-7.
21. Morlet JS, Makin MK. Letter to the editor. Pain 1997; 70: 109-15.
22. Mercadante S, Casuccio A, Calderone L. Rapid Switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 1999; 17: 3307-12.
23. Cancer Pain Relief. World Health Organization, Geneva 1986.
24. th World Congress on Pain, 1999.
25. th World Congress on Pain, 1999. p. 323.
26. Centeno C. Subcutaneous methadone: a valid alternative in the treatment of cancer pain. Abstracts of the 8th Congress of the European Association for Palliative Care, The Hague, The Netherlands, 2003, April 2-5-2003: 93.